Western blot of pooled tumor lysate confirmed that, compared with tumors from vehicle-treated mice, tumors from regorafenib-treated mice consistently showed elevated levels of cleaved PARP in the GC17-0409, GC28-1107, and GC09-0109 models, although the levels of elevation were variable (Fig. 4), coupled with decreased levels of the antiapoptotic protein survivin. The gene discussed is BIRC5; the disease is neoplasm.